MBC President Reacts to DPH Regulations
MBC President & CEO Robert K. Coughlin did a series of media interviews in response to the Department of Public Health's draft sales and marketing disclosure regulations.
"We continue to be concerned that Massachusetts will now be known as the state with the strictest regulations for our industry. This is not a distinction we think will assist us in our mission to position biotech companies to succeed - which in turn strengthens our economic outlook and improves the lives of patients," Coughlin said.
"As we have stated throughout this process, we fully support the need for transparency and we commend the Governor for his leadership on this issue.
It is clear that we all agree that a narrow focus on sales and marketing activities allows us to address the legislature's concerns, but we strongly maintain that we must protect what has made the Commonwealth a leader in healthcare and life sciences - our world-class research and commitment to clinical trials."
The Public Health Commission will be accepting testimony on the regulations.
Here is a schedule of hearings and directions to submit written testimony.
To review the DPH's draft regulations, click here.
For the DPH presentation on the regulations, click here.
For DPH's press release, click here.